iBio Inc, a biotechnology company, has submitted an amendment to its Registration Statement on Form S-3 in response to comments from the staff of the Securities and Exchange Commission (SEC). The SEC's comments, dated July 3, 2024, addressed concerns regarding the company's Prospectus Summary Overview. Specifically, the SEC requested that iBio Inc provide a more balanced discussion of its platform and AI-engine, including the company's limited operating history, lack of clinical trials for product candidates, and the risks associated with developing and commercializing its products. iBio Inc has updated its Prospectus Summary to reflect these concerns and has also revised its disclosure to substantiate performance and leadership claims about its patented AI-engine and technologies. The amendment was filed concurrently with the response to the SEC's comments on July 25, 2024.

iBio Inc, a biotechnology company, has submitted an amendment to its Registration Statement on Form S-3 in response to comments from the staff of the Securities and Exchange Commission (SEC). The SEC's comments, dated July 3, 2024, addressed concerns regarding the company's Prospectus Summary Overview. Specifically, the SEC requested that iBio Inc provide a more balanced discussion of its platform and AI-engine, including the company's limited operating history, lack of clinical trials for product candidates, and the risks associated with developing and commercializing its products. iBio Inc has updated its Prospectus Summary to reflect these concerns and has also revised its disclosure to substantiate performance and leadership claims about its patented AI-engine and technologies. The amendment was filed concurrently with the response to the SEC's comments on July 25, 2024.